Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lol if you say so. Have a good one.
Seems like it
Lol It's understandable since it doesn't show up unless you click 'more'.
They supplied Fins Report in May (10-Q).
Weird. They had a big jump in PPS on that day unlike the other CE removed stock
That's good to see.
Welp, Entrex is chugging along. Here's a new PR:
https://blockchain.entrexcarbonmarket.com/EntrexNewsFAQs.nsf/0/9A5422A8B76CE4838525885B004EEB8D/%24File/06-06-2022%20-%20Entrex%20CarbonEase%20Press%20Release.pdf?Open
Let's go Paul. Fix this ticker so we can merge with Entrex!
Entrex launches 2022 CarbonEase, a $200 million carbon offset asset backed CUSIP security promulgated by SEC Rule 144A.
Boca Raton, Fla., June 3, 2022: Entrex Carbon Market, LLC today announced the launch of 2022 CarbonEaseTM, an asset backet CUSIP security based upon carbon offsets. This $200 million offering is backed by compliance-grade carbon offsets generated by the afforestation and gas sequestration projects directed by Entrex in the US with project management and oversight from KPMG US, LP.
“CarbonEase provides institutional buyers and traders with the convenience, confidence and comfort of a security based on carbon offsets with end-to-end authentication and provenance overseen by KPMG,” said Stephen H. Watkins, CEO of Entrex. “These Rule 144A securities can be acquired through the conventional broker/dealer channel and can be held, traded or retired as the buyer sees fit,” he continued.
“The voluntary carbon offset industry has grown into a $10 billion a year market,” said Tom Harblin, Partner of Entrex Carbon Market. “By creating a tradeable security based on compliance-grade carbon offsets, we’re helping the industry achieve a new level of legitimacy and transparency,” continued Harblin.
###
About Entrex:
Entrex Holding Company, LLC (EHCo, LLC) was founded in 2001 as a capital market system for entrepreneurial companies. The company establishes regulatory-compliant niche capital market systems which support regulated market constituents in originating, structuring, placing, trading, settling and servicing securities of entrepreneurial companies. Working together with industry leaders, Entrex platforms allow investors to find, research, track, manage, and trade entrepreneurial securities by geography, sector or commodity. Entrex Carbon Market, LLC is a majority-owned subsidiary of Entrex Holding Company. CarbonEase is a product of the Entrex Carbon Offset Company, LLC.
Forward-looking Statements:
This press release includes statements of the Company’s expectations, intentions, plans and beliefs that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to come within the safe harbor protection provided by those sections. These statements, which involve risks and uncertainties, relate to the discussion of the Company’s business strategies and its expectations concerning future operations, margins, sales, new products and brands, potential joint ventures, potential acquisitions, expenses, profitability, liquidity and capital resources and to analyses and other
Entrex Carbon Market, LLC • 150 East Palmetto Park • Eighth Floor • Boca Raton, FL 33432 (561) 465-7580 • www.entrexcarbonmarket.com
information that are based on forecasts of future results and estimates of amounts not yet determinable. These also include statements relating to the anticipated benefits of the announced transaction between the Company and Entrex. These statements include any statement that does not directly relate to a historical or current fact. You can also identify these and other forward-looking statements by the use of such words as "may," "will," "should," "expects," "intends," "plans," "anticipates," "believes," "thinks," "estimates," "seeks," "predicts," "could," "projects," "potential" and other similar terms and phrases, including references to assumptions.
These forward-looking statements are made based on expectations and beliefs concerning future events affecting the Company and are subject to uncertainties, risks and factors relating to its operations and business environments, all of which are difficult to predict and many of which are beyond its control, that could cause its actual results to differ materially from those matters expressed or implied by these forward-looking statements. These risks include the Joint Venture’s ability to successfully pursue its business plan, the possibility that the Company’s equity interest in the Joint Venture may be diluted as a result of capital raises by the Joint Venture, the possibility that Entrex may have the right to repurchase the previously contributed assets for nominal consideration, the Company’s ability to develop and commercialize new technologies, the Company’s history of losses and expectation of further losses, its ability to expand its operations into blockchain technologies, its ability to develop or acquire new brands, the success of its marketing activities, the effect of competition in its industry and economic and political conditions generally, including the current economic environment and markets. More information about these and other factors are described in the reports the Company files with the Securities and Exchange Commission, including but not limited to the discussions contained under the caption “Risk Factors.” When considering these forward-looking statements, you should keep in mind the cautionary statements in this press release and the reports the Company files with the Securities and Exchange Commission. New risks and uncertainties arise from time to time, and the Company cannot predict those events or how they may affect it. The Company assumes no obligation to update any forward-looking statements after the date of this press release as a result of new information, future events or developments, except as required by the federal securities laws.
For further information:
Stephen H. Watkins, CEO
Entrex Carbon Market
(561) 465-7580 or 877-4-ENTREX www.entrexcarbonmarket.com
That's a good read. Anyone know what the next Phase entails after Phase 2 for QIXLEEF?
This excellent news. During the Annual meeting, Guy mentioned there were delays approving all non Covid drugs in Canada. It’ll happen. We just need patience.
TBPMF
Yes, Watkins is still interested in UNSS as far as I know. Having said that, Paul needs to get Letter of Attorney to get CE removed or we are dead in the water.
Thanks for sharing.
Hopefully. Right now, we're all in the dark. It would be nice for Paul to provide an update...to anyone!
I was on the road for work so I didn’t attend either.
Tetra Bio-Pharma will host a live webcast of its 2022 Annual Meeting of Shareholders on Monday, May 30, 2022, at 2:00 PM EST. The meeting will be held in a virtual format only and can be accessed at https://meetnow.global/MLKPF2U.
The presentation slides will be available on Tetra’s website after the Meeting: www.tetrabiopharma.com.
Good article. I just wished we had an update on Phase 2 results.
I emailed him, late yesterday. Once in a while he responds, but nothing so far today.
I really wish I knew what the issues are. Getting an Attorney Letter is not usually that hard. We're at Paul's mercy to get things done, obviously. Let's hope he succeeds!
UNSS Long (and not so strong Lol)
'...he said “not much longer”...'
Was this in reference to Attorney Letter?
News!
https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2022/Tetra-Bio-Pharma-Announces-Closing-of-First-Tranche-with-Cannvalate/default.aspx
Tetra Bio-Pharma Announces Closing of First Tranche with Cannvalate
05/17/2022
OTTAWA, ON, May 17, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the closing of the first tranche of the previously announced private placement with Cannvalate Pty Ltd ("Cannvalate"), resulting in the issuance of 8,236,681 common shares in the capital of the Company (the "Common Shares"), representing 1.95% of the issued and outstanding Common Shares, at a price of $0.06 per Common Share for proceeds to the Company of $0.5 million.
Tetra Bio-Pharma Inc. Logo (CNW Group/Tetra Bio-Pharma Inc.)
The subscription price per Common Share issuable under the first tranche was at a discount of 7% to the 5-day VWAP of the Common Shares on the Toronto Stock Exchange ("TSX") on May 4, 2022, the day of execution of the subscription agreement. This first tranche of seven (7) distinct tranches, which will result in aggregate proceeds of $7,500,000 to the Company, triggers the collaboration with iNGENu that will lead to the initiation of the REBORN©1 clinical trial in Australia.
Dr. Guy Chamberland, CEO and CRO of Tetra stated, "We are encouraged by the partnership with Cannvalate and iNGENu as it will allow the Company to further advance our QIXLEEF™ drug program, a promising alternative to opioids. Many investigational new drugs fail trying to carve a use in the management of severe pain. Our interim clinical data demonstrates that QIXLEEF™ has the potential to make a significant difference in patients. Our new partners join us in the race to bring alternatives to pain management."
Partnership with Cannvalate
As previously announced, Tetra has entered into a research agreement with Cannvalate for the performance of clinical trials of Tetra's drug candidates in Australia. Cannvalate is a medical cannabis company bringing in safe and effective cannabinoid-based products to the Australian market. Cannvalate's wholly owned entity, iNGENu, is one of the largest global CROs specializing in cannabinoid clinical trials. Conducting Tetra's clinical trial activities in Australia with iNGENu will allow the Company to benefit from a 43.5% tax credit on all money spent on clinical trials in Australia, and an increased access to patients seeking participation in trials where the pharmaceutical cannabis drug is provided at no cost. Through the Cannvalate partnership, Tetra aims to efficiently assess the clinical viability of its drug products, as well as any new products developed.
About QIXLEEF ™
QIXLEEF™ is the Company's proprietary investigational new drug currently being studied in two U.S Food and Drug Administration (FDA) authorized clinical trials. QIXLEEF™ is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). The drug is inhaled using a medical vaporizer and manufactured in Canada in a licensed current good manufacturing practice (cGMP) facility authorized by Health Canada.
About REBORN©1 - Clinical Trial
REBORN©1 is a Phase 2 study authorized by the U.S. FDA to evaluate inhaled cannabinoids against a class of immediate-release oral opioids for the management of breakthrough cancer pain (BTcP). The study consists of a 10-week proof-of concept, open-label randomized study to evaluate the effect of inhaled QIXLEEF™ as compared to morphine sulfate or hydromorphone or oxycodone for the treatment of BTcP in 20 patients.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Their evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what they do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians, and insurance companies.
For more information: www.tetrabiopharma.com
Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.
Yes indeed!!!
Exactly. Once Letter is submitted, it’s all in OTCs hands to review and remove CE.
UNSS Status is now: Pink Limited
The Dark Defunt with Grace Period is now removed. Looks like Paul avoided UNSS going Grey and in Expert Market - Crisis averted.
Looks like 2022 Q1 Fins are submitted as well (my bad, forgot it was due as well)
I could be wrong but I don’t believe Q4 is needed when the Annual Fins are provided.
Great news, thanks for sharing!
Hard to say. There is no info, positive or negative.
If OTC approves their content, then it will be enough.
Pretty much all OTC penny stocks have been doing badly for a very long time. Eventually, companies with real value like TBPMF will bounce back IMHO.
Good news. Thanks for sharing.
Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology
Panag Pharma Inc (Panag), a subsidiary of Tetra Bio-Pharma, will collect royalties on sales on products produced with the technology True North has licensed from Panag.
Use of a highly innovative proprietary liposome encapsulated technology leads to a better CBD absorption.
This New True North Nectar product line in liquid and powder formats are expected to launch in select markets in Q4 2022.
OTTAWA, ON, May 10, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development in collaboration with Panag, a subsidiary of Tetra Bio-Pharma, and True North Cannabis Corp (True North), today announced it has entered into a technology licensing agreement allowing True North to use its highly innovative proprietary liposome encapsulated technology within formulations distributed under the True North brand.
Tetra Bio-Pharma Inc. logo (CNW Group/Tetra Bio-Pharma Inc.)
Tetra's patented technology leads to better absorption and aqueous emulsification of the CBD molecule in a variety of products. Panag will work with True North's product team to integrate this technology and develop a line of hemp-derived CBD formulations, for True North and its partners to commercialize through their existing distribution relationships in both the medical and recreational markets in Canada
About the Technology
In developing these products, the Panag team is using Tetra's liposome encapsulated technology, a patented process to encapsulate and protect the active molecules into a multi-layered sphere. Delivery of the formulation is greatly improved by enhancing the dispersion of loaded liposomal spheres within an aqueous (water-based) environment.
"This opportunity is the beginning of a great relationship between the two companies. Panag has enjoyed working closely with the True North team and we are very excited at the expansion of our pipeline with innovative wellness products that fit within their portfolio, in the competitive and growing CBD market," said Chris MacLean, COO of Panag Pharma.
"I am glad that this highly innovative and patented technology will benefit the wellness market. We are adapting our pharmaceutical technologies for the benefit of True North customers," said Steeve Néron, CCO of Tetra BioPharma.
"True North is pleased to have entered into a licensing agreement with Panag Pharma Inc. to exclusively incorporate their molecular technology into product formulations distributed under the True North brand. Panag's patented CBD encapsulation technology is expected to further differentiate True North's branded product offering in the highly competitive medical and recreational CBD product market. True North looks forward to bringing an exciting array of innovative products utilizing this technology to consumers across the country," said Brett Halvorson, President & CFO of True North.
About True North
True North Cannabis Corp. is a Canadian hemp-based CBD products company. True North and its partners supply value priced CBD bulk ingredients to licensed producers across Canada, and deliver a range of extracted and edible CBD products to patients and consumers alike through the True North brand. For more information, please visit www.truenorthcannabis.com.
About Panag Pharma
Panag Pharma Inc. is a Canadian based bio-tech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Panag believes that pain relief should be safe, non-addictive and above all; effective. The Panag Pharma team of PhD scientists and medical doctors are among the world's leading researchers and clinicians in pain treatment and management. They bring a combined experience of over 100 years in research and clinical care of people dealing with chronic pain and inflammatory conditions. Panag's development pipeline of pain relief products include topical, oral, and ocular delivery solutions for challenging molecules.
If the attorney is ok with the filings as is, then he will issue the letter.
News! Tetra Bio-Pharma and Cannvalate Enter Into Partnership
https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2022/Tetra-Bio-Pharma-and-Cannvalate-Enter-Into-Partnership/default.aspx
Tetra Bio-Pharma and Cannvalate Enter Into Partnership
05/05/2022
Cannvalate to invest CAD$7.5M in Tetra.
Cannvalate to launch and manage QIXLEEF™ and CAUMZ™ clinical trials in Australia.
The Company to benefit from a 43.5% tax credit on all money spent on clinical trials in Australia.
OTTAWA, ON, May 5, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development, today announced it has entered into a research and development agreement with Cannvalate Pty Ltd ("Cannvalate") for the initiation of the REBORN®, PLENITUDE® and CAUMZ® clinical trials in Australia, and a subscription agreement contemplating a private placement (the "Private Placement") of common shares in the capital of the Company (the "Common Shares") with Cannvalate for aggregate proceeds to the Company of up to CAD$7,500,000.
Tetra Bio-Pharma Logo (CNW Group/Tetra Bio-Pharma Inc.)
The Company has also appointed Dr. Sud Agarwal as a Special Advisor to the CEO and the board of directors with a mandate to advise on strategic aspects of the Company's activities and to aid in the advancement of our key programs: QIXLEEF™ and CAUMZ™.
Partnership with Cannvalate
Tetra has entered into a research agreement with Cannvalate for the performance of clinical trials of Tetra's drug candidates in Australia. Cannvalate is a medical cannabis company bringing in safe and effective cannabinoid-based products to the Australian market. Cannvalate's wholly owned entity, iNGENu, is one of the largest global CROs specializing in cannabinoid clinical trials. By conducting Tetra's clinical trial activities in Australia with iNGENu, it will allow the Company to benefit from a 43.5% tax credit on all money spent on clinical trials in Australia, and an increased access to patients seeking participation in trials where the pharmaceutical cannabis drug is provided at no cost. Through the Cannvalate partnership, Tetra aims to efficiently assess the clinical viability of its drug products, as well as any new products developed.
Dr. Guy Chamberland, CEO and CRO of Tetra stated, "We have been developing inhaled cannabinoid drugs since 2016 and have a wealth of data to support the potential development of a new generation of drugs to help patients suffering from chronic diseases. It takes years of research and development to have a drug in two Phase 2 trials designed to support drug approval in the USA and Europe. Finding ways to accelerate timelines while reducing the monthly burn is a continuous battle for all biotechnology companies. This partnership is intended to allow Tetra to achieve both goals."
Private Placement
Cannvalate also agreed to acquire Common Shares of Tetra on a private placement basis, through seven (7) distinct tranches, for aggregate proceeds of CAD$7,500,000. The first tranche providing for the issuance of Common Shares having an aggregate subscription price of CAD$500,000 was triggered by the signing of the subscription agreement, whereas the subsequent tranches of the Private Placement will be triggered by the completion of various operational events in connection with the REBORN®, PLENITUDE® and CAUMZ® clinical trials, such as the achievement of first patient enrolments in each such trial. The Company intends to use the proceeds of the Private Placement to fund its clinical trials and R&D activities in collaboration with Cannvalate and iNGENu.
The subscription price per Common Share issuable under the first tranche will be at a discount of 7% to the 5-day VWAP of the Common Shares on the Toronto Stock Exchange ("TSX") on the day of execution of the subscription agreement with respect to the Private Placement. Subject to compliance with the rules and regulations of the TSX, the subscription price per Common Share issuable under the second and third tranches will be at a discount of 7%, whereas the subscription price per Common Share issuable under the fourth to seventh tranches will be at a discount of 20%, in each case based on to the 5-day VWAP of the Common Shares on the TSX prior to the date of the issuance of the respective tranche. In accordance with the terms of the Private Placement, the subscription price per Common Share shall be adjusted upwards to ensure that Cannvalate and its affiliates shall not beneficially own, or have control or direction over, Common Shares in excess of 19.99% of the number of Common Shares issued and outstanding immediately after giving effect to the issuance of Common Shares issuable under the applicable tranche.
Upon completion of the fifth tranche of the Private Placement which will result in the Company having received aggregate proceeds of CAD$4,500,000, the Company will enter into a nomination right agreement with Cannvalate providing for the grant of a seat on Tetra's board of directors to Dr. Sud Agarwal for so long as Cannvalate owns or exercises control or direction, directly or indirectly, over 10% or more of the issued and outstanding Common Shares. Guy Chamberland, CEO and CRO of Tetra stated, "Dr. Agarwal will bring both inhalation clinical expertise and cannabinoid drug development experience to Tetra's board. His addition will further strengthen our board as we continue to evolve into a cannabinoid pharmaceutical company."
The securities issued pursuant to the Private Placement will be subject to a four-month hold period from the date of their respective issuance. Completion of the Private Placement remains subject to the receipt of all necessary regulatory approvals, including the approval of the TSX.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any securities of the Company in the United States. The securities described in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended ("U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
About Dr. Sud Agarwal BSc, MB ChB, FANZCA
Dr. Sud Agarwal is the Co-Founder and CEO of Cannvalate and iNGENu, a globally renowned contract research organisation in the cannabinoid space. Dr. Agarwal is an internationally recognised key opinion leader in the clinical use of medicinal cannabis and is regularly invited as a keynote to key industry and pharmaceutical events. His research interests include synthetic cannabinoid drug development, novel inhalational cannabinoids drug-device combinations and cannabinomimetic analogues.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Their evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what they do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians, and insurance companies.
For more information visit: www.tetrabiopharma.com
Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this news release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements in the news release include, without limitation, statements with respect to clinical trials for the Company's drug candidates and expected timing thereof, the benefits expected to be derived by the Company from the partnership with Cannvalate, the expected closing of the tranches under the Private Placement and timing thereof, the expected aggregate proceeds to be received by the Company under the Private Placement, the receipt of regulatory approval with respect to the Private Placement, including the receipt of TSX approval, the expected use of the proceeds under the Private Placement and the appointment of Dr. Sud Agarwal to the board of directors of the Company. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/tetra-bio-pharma-and-cannvalate-enter-into-partnership-301540349.html
SOURCE Tetra Bio-Pharma Inc.
According to Paul, Filings are 'FINALLY' getting reviewed by lawyer. 'Stay tuned'.
I was checking that today, as well. No CE removal for over 2 months! Kind of weird to be honest.
MMs suck Lol
Thanks for doing this and sharing. Very good email to him.
At the end of day, it is in his own interest to get the CE removed so let’s hope he can get it done.
Current PPS matters little since this is a long term play. If TBP succeeds in bringing QIXLEEF into multi billion dollar pain killer market, PPS will reach dollars.
Agreed, I noticed this as well.
Once both are submitted, everything will be in the hands of the OTC. At a minimum it should get them back to OTC Current.
If they are satisfied UNSS meets all conditions, then they will remove the CE. If not, it's back to the drawing for UNSS and its Legal Counsel.
Update from Paul:
He says he won't issue Fins until Letter of Attorney is ready for which he has submitted all the requested info to Legal Counsel.
I'm not going to put a timeline here since that has lead to disappointment here, but I am cautiously optimistic he is close. Let's hope!